ProfileGDS5678 / 1419113_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 73% 73% 72% 73% 74% 74% 73% 75% 73% 73% 74% 73% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.7664574
GSM967853U87-EV human glioblastoma xenograft - Control 24.7695873
GSM967854U87-EV human glioblastoma xenograft - Control 34.771973
GSM967855U87-EV human glioblastoma xenograft - Control 44.7476972
GSM967856U87-EV human glioblastoma xenograft - Control 54.7190573
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7887974
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8041774
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7479773
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0170275
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.7845373
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.7003273
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8221174
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.746873
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.7546274